Drug Profile
AEG 33773
Alternative Names: AEG33773Latest Information Update: 02 Jun 2011
Price :
$50
*
At a glance
- Originator Aegera Therapeutics
- Class Analgesics; Small molecules; Sulfonamides; Thiadiazoles
- Mechanism of Action JNK mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetic neuropathies
Most Recent Events
- 02 Jun 2011 No development reported - Phase-II for Diabetic neuropathies in Canada (PO)
- 02 Jun 2011 No development reported - Phase-II for Diabetic neuropathies in Europe (PO)
- 02 Jun 2011 No development reported - Phase-II for Diabetic neuropathies in USA (PO)